FDA-Approved Stimulant Medications
The FDA-approved stimulants for ADHD treatment include methylphenidate-based compounds (MPH), amphetamine-based compounds (AMP, DEX), dextromethylphenidate, mixed amphetamine salts, and lisdexamfetamine dimesylate (LDX), with modafinil approved for narcolepsy but used off-label for ADHD. 1
Core Stimulant Categories
The FDA-approved stimulants fall into two primary chemical classes:
Methylphenidate-Based Stimulants
- Methylphenidate (MPH) - Available in multiple formulations 1
- Dextromethylphenidate (Focalin, Focalin-XR) - The active D-isomer of methylphenidate 2, 3
Amphetamine-Based Stimulants
- Dextroamphetamine (DEX) 1
- Amphetamine (AMP) 1
- Mixed amphetamine salts (Adderall, Adderall-XR) 2, 3
- Lisdexamfetamine dimesylate (Vyvanse/LDX) - A prodrug of d-amphetamine with reduced abuse potential 3
Available Formulations
Since 2012, the FDA has approved 11 novel stimulant formulations, expanding treatment options significantly 4. The 19 different formulations available include 2:
Once-Daily Extended-Release Options
- Concerta (methylphenidate ER)
- Focalin-XR (dextromethylphenidate ER)
- Adderall-XR (mixed amphetamine salts ER)
- Vyvanse (lisdexamfetamine) - unique prodrug delivery system
- Metadate-CD (methylphenidate ER)
- Ritalin-LA (methylphenidate ER)
Alternative Delivery Systems
- Daytrana - Transdermal methylphenidate patch, allowing patient control over dosing duration and an option for children who cannot swallow pills 2
Flexible Administration
Several extended-release capsules (Focalin-XR, Adderall-XR, Metadate-CD, Ritalin-LA) can be opened and sprinkled on applesauce for patients unable to swallow tablets 2
FDA-Approved Indications
The primary FDA-approved indications for stimulants are 1:
- ADHD (children, adolescents, and adults)
- Narcolepsy (characterized by irresistible daily sleep attacks over at least 3 months)
Key Distinguishing Features
Lisdexamfetamine (Vyvanse) represents a significant advancement due to its prodrug formulation, which provides:
- Lower intersubject variability in pharmacokinetics compared to mixed amphetamine salts-XR
- Significantly reduced abuse potential (P = 0.039 in studies of adults with stimulant abuse history)
- Consistent duration of effect throughout the day 3
Mechanism of Action
All approved stimulants work primarily as substrates for cellular monoamine transporters, particularly the dopamine transporter (DAT) and to a lesser extent the norepinephrine transporter (NET), increasing extracellular dopamine, norepinephrine, and serotonin 5
Important Clinical Caveat
While modafinil is FDA-approved for narcolepsy and has demonstrated efficacy in ADHD symptom improvement, it is not FDA-approved specifically for ADHD treatment and remains an off-label option 5.